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Abstract The prevalence of smoking was studied using a questionnaire. Pulmonary function
tests and respiratory symptoms were evaluated in 176 smokers. The total studied population
with family and co-workers were 13289. The number of smokers among studied population was
11.7%. The rate of smoking among male subjects was 17.2% and in female 2.5%. All values of
PFTs in smokers were signiﬁcantly lower (p < 0.001) and respiratory symptoms higher than in
non smokers (p < 0.05 for cough and p < 0.001 for wheeze and tightness). There were signiﬁcant
negative correlations between smoking duration and rate with values of PFT (p < 0.05-p < 0.001).
In this study the prevalence of smoking in population of Mashhad city was shown. The preva-
lence of smoking was higher among male than females. Smoking leads to increased respiratory
symptoms and reduction of PFTs values.
© 2010 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.
PALABRAS CLAVE
Prevalência do acto
de fumar;
Durac¸ão do acto de
fumar;
Testes de func¸ão pulmonar e sintomas respiratórios em fumadores iranianos
Resumen A prevalência do acto de fumar foi estudada através de um questionário. Os testes
de func¸ão pulmonar e sintomas respiratórios foram avaliados em 176 fumadores. O total da
populac¸ão estudada com família e colaboradores foi de 13289. O número de fumadores entre aQuantidade do acto
de fumar;
Testes de func¸ão
pulmonar;
Sintomas
respiratórios
populac¸ão estudada foi de 11,7%. A taxa do acto de fumar entre os homens foi de 17,2% e de 2,5%
entre as mulheres. Todos os valores de TFP nos fumadores foram signiﬁcativamente inferiores
(p < 0.001) e os sintomas respiratórios foram superiores em relac¸ão aos não fumadores (p < 0,05
para tosse e p < 0,001 para pieira e aperto torácico). Registaram-se correlac¸ões negativas signi-
ﬁcativas entre a durac¸ão do acto de fumar e a taxa com valores de TFP (p < 0,05-p < 0,001). Neste
estudo, foi apresentada a prevalência do acto de fumar na populac¸ão da cidade de Mashhad.
∗ Corresponding author.
E-mail addresses: boskabadymh@mums.ac.ir, mhboskabady@hotmail.com (M.H. Boskabady).
0873-2159/$ – see front matter © 2010 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.
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A prevalência do acto de fumar foi maior entre os homens do que entre as mulheres. Fumar
leva a um aumento de sintomas respiratórios e à reduc¸ão dos valores de TFP.
© 2010 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
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ﬂow (MMEF) and maximal expiratory ﬂow at 75%, 50%, and
25% of the FVC (MEF75, MEF50, and MEF25 respectively) were
taken independently from the three curves. The study was
Table 1 The age distribution among studied population.
Age (years) Male Female Total
10-19 14 15 29
20-29 175 53 228
30-39 285 114 399
40-49 267 132 399
50-59 162 73 235direitos reservados.
ntroduction
hronic obstructive pulmonary disease (COPD) is a major
ause of chronic morbidity throughout the world. Many peo-
le suffer from this disease for years and die prematurely
rom it or its complications. COPD is currently the fourth
eading cause of death in the world1 and further increases in
ts prevalence and mortality can be predicted in the coming
ecades.2
Cigarette smoking is by far the most important risk factor
or COPD and the most important way that tobacco con-
ributes to the risk of COPD.3 Cigarette smokers have a
igher prevalence of respiratory symptoms and lung function
bnormalities, greater annual rate of decline in FEV1 and a
reater COPD mortality rate than non-smokers.4 These dif-
erences between cigarette smokers and non-smokers are
n direct proportion to the quantity of smoking. Smoking
eads to rapid decline in pulmonary function tests (PFTs) spe-
ially those indicating diameter of the airways such as forced
xpiratory ﬂow in one second (FEV1).5 Even in teenagers
ho have smoked only a few years, maximum expiratory
ow-volume curves demonstrate decreases in ﬂow rates at
mall lung volumes,6 yet another expression of small air-
ay obstruction. Until now, the only well-documented acute
ffect of smoking on the airways was the decrease of air-
ay conductance demonstrated by Nadel and Comroe.7 The
bstruction to airﬂow that develops in 15 to 20% of heavy
mokers is thought to be due to abnormalities in airways
ess than 2mm internal diameter.8 Previous studies from sev-
ral laboratories have shown that this airway obstruction is
ssociated with a chronic inﬂammatory process in the mem-
ranous and respiratory bronchioles.9,10 It is believed that
he airway constriction in COPD and decline in PFTs is not
eversible.
Therefore, in the present study the prevalence of smok-
ng in the city of Masshad and the effect of quantity and
uration of smoking on PFTs and the respiratory symptoms
ere examined.
ethods
tudy area and population
he data of directly interviewed subjects (1435 subjects
ncluding 999 male and 436 female) and their relatives
totally 13289 subjects) aged 10 year and over (Table 1)
egarding prevalence of smoking were collected from 21 ran-
omly selected areas in the city of Mashhad using clustering
ampling method and a list of different areas of the city.
he city of Mashhad has moderate industry and heavy traf-
c. Mashhad is a holy city located in the north east of Iran
ith a population of two-million people, many of whom are
mmigrants from all over Iran.rotocol
Farsi questionnaire was used to assess the prevalence
f smoking among population of the city of Mashhad and
he respiratory symptoms. The questionnaire included two
ifferent parts: 1) part (a) questions on regular smoking,
mount and duration of smoking and 2) part (b) respira-
ory symptoms (wheezing, tightness, cough and sputum).
he interviewed subjects were asked the questions from
oth parts but relatives of interviewed subjects were only
sked questions from part (a). In addition, 150 non smok-
rs of similar age and sex distribution were interviewed
nd their respiratory symptoms were evaluated as a control
roup. The studied (interviewed subjects) were interviewed
ace to face by two trained ﬁnal medical students. The
uestionnaire was validated in our two previous studies.11,12
he questionnaire on respiratory symptoms was designed in
ccordance with several previous questionnaires of similar
tudies by expert groups,13—15 (Table 2).
Pulmonary function tests of smokers and control groups
ere measured using a spirometer with a pneumotacho-
raph sensor (Model ST90, Fukuda, Sangyo Co., Ltd. Japan).
rior to pulmonary function testing, the required manoeu-
re was demonstrated by the operator, and subjects were
ncouraged and supervised throughout the test perfor-
ance. Pulmonary function testing was performed using the
cceptability standards outlined by the American Thoracic
ociety (ATS) with subjects in a standing position and wear-
ng nose clips.16 All tests were carried out between 1000 and
700 hours. Pulmonary function tests were performed three
imes in each subject with an acceptable technique. Sub-
ects were educated prior to PFT measurements regarding
he PFT performance. PFT measurements were carried out
hree times in each subject and there were small variation
mong three measurements. The highest level for forced
ital capacity (FVC), forced expiratory volume in one second
FEV ), peak expiratory ﬂow (PEF), maximal mid expiratory60-69 68 42 110
> 70 28 7 35
Total 999 436 1435
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Table 2 The criteria for asthma severity score.
Symptom Frequency Score
Wheezing None 0
During mild exercise (walking) 1
During heavy exercise 2
At rest 3
Cough None 0
During mild exercise (walking) 1
During heavy exercise 2
At rest 3
Tightness None 0
During mild exercise (walking) 1
During heavy exercise 2
At rest 3
Sputum None 0
Small volumes of non purulent sputum 1
Large volumes of non purulent sputum 2
Purulent sputum 3
Total score 12
Table 3 Prevalence of smoking among population of differ-
ent region and total studied subjects in the city of Mashhad.
Region Studied
Subjects
Smokers Prevalence
(%)
Faramarz Abasi Bulv. 275 33 12%
Azad Shahr 985 105 10.6%
Sajad Bulv 621 62 10%
Vakil Abad Bulv 995 110 11%
Pirozi Bulv, Reza Shahr 748 77 10.3%
Vahdat Bulv 617 78 12.6%
Saydi 598 79 13.2%
Shahid Mofateh Bulv 621 77 12.4%
Kalat Road 427 50 11.7%
Resalat Bulv 646 70 10.8%
Gol Shahr 603 88 14.6%
Tabarsi Bulv 702 91 13%
Najaﬁ Shahrak, Hor Sq. 910 110 12%
Farhang Bulv 623 70 11.2%
Andishah Bulv 624 74 11.8%
Ahmad Abad, Ghaem 621 55 8.9%
Behshti St. 623 74 11.8%
Imam Reza St. 900 115 12.8%
Ghasem Abad 600 70 11.7%
Eshrat Abad Cross 260 30 11.5%
Northern Shahrokh 290 36 12.4%
Total 13289 1554 11.7%
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except sputum (p < 0.05 to p < 0.001), (Table 4).
The severity of most respiratory symptoms was also
greater in smokers compared to non smoker subjects which
Table 4 Comparison of respiratory symptoms severity
between smokers and non-smokers.
Respiratory
symptoms
Smokers Non-smokers Statis. dif.
Wheezing 0.48 ± 0.88 0.16 ± 0.59 p < 0.05
Tightness 0.62 ± 0.90 0.31 ± 0.90 p < 0.05
Cough 0.28 ± 0.67 0.18 ± 0.75 NS
Sputum 0.25 ± 0.53 0.26 ± 0.81 NSapproved by the ethical comity of Mashhad University of
Medical Sciences.
Data analysis
Based on the prevalence of smoking in Iran,17,18 using
the PPS sampling method, it was calculated that a mini-
mum of 1300 subjects (900 male and 400 female) would
be needed to detect a 5% difference with an ( error of
1% and a power of 95%. Therefore, 1435 subjects includ-
ing 999 male and 436 female were interviewed. The data
of PFT values and age were expressed as mean± SD and
data of smoking and respiratory symptoms as percentage
of each group having the correspond symptom. Differences
in the data of symptoms between smokers and control
group were tested by Chi-Squared analysis on 2X2 contin-
gency tables. The data of PFT values between smokers
and control group were compared using unpaired t test.
The relationships between PFT values and respiratory symp-
toms with duration and quantity of smoking were performed
using regression analysis. A two-sided p value of 0.05 was
the criterion for statistical signiﬁcance. All analyses were
performed with SPSS software (version 11.5, SPSS Inc.
USA).
Results
Prevalence of smoking
The prevalence of smoking among all studied individuals
including relatives of interviewed subjects was 11.7% (1554
out of 13289 subjects), (Table 3).
Smoking wasmore prevalent among population of Golshar
area and less prevalent in Ahmad Abad area (a poor and
rich populated area of Mashhad city respectively). Generally
smoking was more prevalent in poorer populated area of theStu: studied subjects, S.: Smokers, %: prevalence of smoking
(percentage).
ity (Table 3). The prevalence of smoking was much lower
n female (2.5%) compared to male (17.2) subjects.
espiratory symptoms
he most and the least prevalent respiratory symptoms
mong smokers were tightness and cough respectively.
bout one third (34%) of smokers reported tightness and
nly 17% had cough symptom. However, the prevalence of all
espiratory symptoms among smokers was higher compared
o those in control group which was statistically signiﬁcantValues were presents as mean± SD, NS: non signiﬁcant differ-
ences. Differences in the data of symptoms between smokers
and control group were tested by Chi-Squared analysis on 2X2
contingency tables.
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Figure 1 Comparison of prevalence of respiratory symptoms
(percentage of subjects of each group having the corresponding
symptoms) between smokers (lighter ﬁlled bars) and non-
smokers (darker ﬁlled bars), (for smokers and non smokers
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Table 5 Relationship between respiratory symptoms
in smokers with smoking duration (year) and amount
(pack/year).
Respiratory symptoms Duration Amount
R P R P
Wheezing 0.158 p < 0.05 0.087 NS
Tightness 0.146 NS 0.008 NS
Cough 0.044 NS 0.027 NS
Sputum 0.141 NS 0.036 NS
NS: non signiﬁcant differences. The relationships between res-
piratory symptoms with duration and quantity of smoking were
performed using regression analysis.
Table 6 Relationship between pulmonary function tests
(PFT) of smokers with smoking duration (year) and amount
(pack/year).
PFT Values Duration Amount
R P R P
FVC -0.224 p < 0.01 -0.127 NS
EFV1 -0.282 p < 0.001 -0.163 p < 0.05
MMEF -0.306 p < 0.001 -0.137 NS
PEF -0.241 p < 0.005 -0.121 NS
MEF75 -0.247 P < 0.005 -0.170 p < 0.05
MEF50 -0.305 P < 0.001 -0.144 NS= 176 and 150 respectively). NS: non signiﬁcant differences,
: p < 0.05, ***: p < 0.001.
as statistically signiﬁcant for wheezing and breathlessness
p < 0.05 for both cases), (Fig. 1).
ulmonary function test
lthough some values of pulmonary function tests in smokers
ere around normal range of 80% predicted values (MFEF,
EF50 and MEF25), all values of PFT among smokers were
igniﬁcantly lower than those of non smokers (p < 0.001 for
l cases), (Fig. 2).
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igure 2 Comparison of pulmonary function tests (Mean± SD)
etween smokers (lighter ﬁlled bars) and non-smokers (darker
lled bars), (for smokers and non smokers n = 176 and 150
espectively). FVC: forced vital capacity, FEV1: forced expira-
ory volume in one second, MMEF: maximal mid expiratory ﬂow,
EF: peak expiratory ﬂow, MEF75, MEF50, and MEF25: maximal
xpiratory ﬂow at 75%, 50%, and 25% of the FVC, respectively.
**: p < 0.001. The data of PFT values between smokers and
ontrol group were compared using unpaired t test.
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dMEF25 -0.236 P < 0.005 -0.072 NS
NS: non signiﬁcant differences.
elationship between smoking duration and
mount with pulmonary function tests and
espiratory symptoms of smokers
he relationship between respiratory symptoms for only
heezing with duration of smoking (year) was statistically
igniﬁcant (p < 0.05), (Table 5). There were signiﬁcant neg-
tive relationships between duration of smoking with all
FT values (p < 0.01 to p < 0.001) and amount of smoking
pack/year) with only FEV1 and MEF75 (p < 0.05 for both
ases), (Table 6).
iscussion
n the present study which was performed in a relatively
arge population sample, the prevalence of smoking in the
ity of Mashhad (north east Iran) was studied. The respira-
ory symptoms and PFT values of smokers in comparison to
on-smokers were also evaluated. The results showed that
1.7% of the population of the city are regular smokers. The
esults also indicated that prevalence of smoking is higher
mong population of poor area of the city.
The prevalence of smoking was much lower in female
2.5%) compared to male (17.2) subjects.
The results of study of Ahmadi et al. showed higher
17revalence of smoking in the city of Shiraz (18.7%). The
ample population of their study was smaller compared
o the present study which might be the reason for the
ifferences in the prevalence of smoking between two
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studies. The other reason for the differences in prevalence
of smoking between Shiraz and Mashhad city could be the
differences in the culture of the populations of the two
cities. In another study, Ahmadi et al. showed a smoking
prevalence of 25% among nursing students in Iran.18 Turcic´
et al., also showed a higher smoking prevalence among
male (27.2%) compared to female subjects (12.6) among
old population of Zagreb.19 However, the difference in the
prevalence of smoking between male and females in this
part of Europe is much lower than that of the population of
Iran.
The results also showed increased respiratory symp-
toms and reduction of all values of pulmonary function
tests in smokers compared to those of non-smoker sub-
jects. Although the mean values of PFTs in smokers were
around the normal range, all PFT values were signiﬁcantly
lower in smokers than non smokers. The increased respi-
ratory symptoms and reduction of PFT values in smokers
showed the effect of smoking on respiratory system. How-
ever, those PFT values indicating the diameter of smaller
airways (MMEF, MEF50 and MEF25) were less affected in
smokers. The relationship between quantity of smoking and
respiratory symptoms was not signiﬁcant but the correla-
tion between only wheezing and duration of smoking was
signiﬁcant. However, there were signiﬁcant and negative
correlations between all PFT values with duration and some
PFT values (FEV1 and FEF75) with quantity of smoking. The
relations between respiratory symptoms and PFT values with
quantity and duration of smoking are further conﬁrmation of
profound effect of smoking on respiratory system.
The results of the study of Turcic´ et al. also showed higher
prevalence of respiratory symptoms including cough and
breathlessness among smokers compared to non smokers19
which support the results of the present study. Rigalado-
Pineda et al. also showed a higher prevalence of respiratory
symptoms among smokers in Mexico population.20 However,
the weak correlations between respiratory symptoms and
both quantity and duration of smoking seen in the present
study is perhaps due to the subjective characteristics of the
symptoms. In addition, the respiratory symptoms occurred
after profound disorder of respiratory system which usually
happened due to long time and high quantity of smoking.
As it is clear in Fig. 1, all respiratory symptoms in smok-
ers are higher than in non smokers which are statistically
signiﬁcant except sputum. The reason that there is no signif-
icant difference in sputum prevalence and severity of cough
and sputum between smokers and non-smokers is perhaps
because of the relatively short duration of smoking among
population of the present study, especially in the younger
age groups and in females which constitute more than two
third of total smokers.
Several previous studies also showed reduction of dif-
ferent values of PFTs among smoker compared to normal
subjects.21—29 The result of the present study showed that
the reduction in PEF and MEF75 among smoker subjects was
signiﬁcantly more than other values of PFTs. These results
may indicate that in smoker subjects, medium and large
airways are more affected by smoking than other airways.
The results of our study were supported by previous stud-
ies indicating reduction of mainly PEF, MMEF and MEF75
in smokers.30—33 However, a study showed that small air-
ways are more affected by smoking.22 In addition, variousers in the city of mashhad (north east of Iran) 203
ther studies showed reduction of other PFT values including
EV1,19,20,34—36 MMEF and MEF50,32 MEF25 and MEF50.19 The
ifferences in reduction of different PFT values in differ-
nt studies could be due to the type of cigarettes smoked,
he age of studied population or duration and/or quantity
f smoking. The results of our previous study in a smaller
opulation and in mild smokers also showed similar results
.e. small airways are more affected by smoking.37 Most of
he above studies also showed reduction in FVC value.
The results of the present study also showed signiﬁcant
egative correlations between all PFTs values with amount
nd duration of smoking. However, correlation between PFTs
alues and durations of smoking was greater than the corre-
ation between PFTs values and quantity of smoking. These
esults showed that duration of smoking has more profound
ffect on airways than quantity of smoking. The studies of
aakkola et al.35 Sherrill et al.38 and Verschakelen et al.39
lso showed correlations between smoking and reduction of
ost PFTs values, supporting the results of the present study.
n addition, Burrows et al also showed quantities relationship
etween cigarette smoking and reduction in PFTs values.5
ur previous study also showed greater correlation between
FTs values and duration of smoking compared to the corre-
ation between PFTs values and quantity of smoking.37
onclusion
n conclusion, the results of the present study showed an
1.7% prevalence of smoking among population of the city of
ashhad. The prevalence of smoking was signiﬁcantly higher
mong males than females. The results also demonstrated
he profound effect of smoking on PFTs specially those indi-
ating large airways. There were also increased respiratory
ymptoms among smokers.
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